An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment

REFERENCES

1. 1.↵
   1. Petersen RC,
   2. Roberts RO,
   3. Knopman DS,
   4. et al

   . Mild cognitive impairment: ten years later. Arch Neurol 2009;66:1447–55

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Petersen RC

   . Clinical practice. Mild cognitive impairment. N Eng J Med 2011;364:2227–34

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Alzheimer A

   . Über eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatr 1907;64:146–48
4. 4.↵
   1. Holtzman DM,
   2. Morris JC,
   3. Goate AM

   . Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011;6:3:77sr1
5. 5.↵
   1. Koffie RM,
   2. Meyer-Luehmann M,
   3. Hashimoto T,
   4. et al

   . Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 2009;106:4012–17

   Abstract/FREE Full Text
6. 6.↵
   1. Kuchibhotla KV,
   2. Goldman ST,
   3. Lattarulo CR,
   4. et al

   . Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 2008;59:214–25

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Kim J,
   2. Basak JM,
   3. Holtzman DM

   . The role of apolipoprotein E in Alzheimer's disease. Neuron 2009;64:632–44

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Jonsson T,
   2. Atwal JK,
   3. Steinberg S,
   4. et al

   . A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012;488:96–99

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Crystal H,
   2. Dickson D,
   3. Fuld P,
   4. et al

   . Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988;38:1682–87

   CrossRef
10. 10.↵
    1. Arriagada PV,
    2. Growdon JH,
    3. Hedley-Whyte ET,
    4. et al

    . Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631–39

    CrossRefPubMed
11. 11.↵
    1. Holmes C,
    2. Boche D,
    3. Wilkinson D,
    4. et al

    . Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216–23

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Braak H,
    2. Braak E

    . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–59

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Roberson ED,
    2. Scearce-Levie K,
    3. Palop JJ,
    4. et al

    . Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007;316:750–54

    Abstract/FREE Full Text
14. 14.↵
    1. Ittner LM,
    2. Ke YD,
    3. Delerue F,
    4. et al

    . Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010;142:387–97

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Desikan RS,
    2. McEvoy LK,
    3. Thompson WK,
    4. et al

    . Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol 2011;70:657–61

    CrossRefPubMed
16. 16.↵
    1. Desikan RS,
    2. McEvoy LK,
    3. Thompson WK,
    4. et al

    . Amyloid-β-associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol 2012;69:709–13

    CrossRefPubMed
17. 17.↵
    1. Hyman BT

    . Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 2011;68:1062–64

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Morris JC,
    2. Price JL

    . Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001;17:101–18

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Sperling RA,
    2. Aisen PS,
    3. Beckett LA

    . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280–92

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Knopman DS,
    2. DeKosky ST,
    3. Cummings JL

    . Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143–53

    CrossRef
21. 21.↵
    1. Vemuri P,
    2. Jack CR Jr.

    . Role of structural MRI in Alzheimer's disease. Alzheimers Res Ther 2010;2:23

    CrossRefPubMed
22. 22.↵
    1. Whitwell JL,
    2. Josephs KA,
    3. Murray ME,
    4. et al

    . MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008;71:743–49

    CrossRef
23. 23.↵
    1. Fischl B,
    2. Salat DH,
    3. Busa E,
    4. et al

    . Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341–55

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Fischl B,
    2. van der Kouwe A,
    3. Destrieux C,
    4. et al

    . Automatically parcellating the human cerebral cortex. Cereb Cortex 2004;14:11–22

    Abstract/FREE Full Text
25. 25.↵
    1. Desikan RS,
    2. Ségonne F,
    3. Fischl B,
    4. et al

    . An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968–80

    CrossRefPubMedWeb of Science
26. 26.↵
    1. McEvoy LK,
    2. Brewer JB

    . Quantitative structural MRI for early detection of Alzheimer's disease. Expert Rev Neurother 2010;10:1675–88

    CrossRefPubMed
27. 27.↵
    1. Holland D,
    2. McEvoy LK,
    3. Dale AM,
    4. et al

    . Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. Hum Brain Mapp 2011;33:2586–602

    PubMed
28. 28.↵
    1. Brewer JB,
    2. Magda S,
    3. Airriess C,
    4. et al

    . Fully-automated quantification of regional brain volumes for improved detection of focal atrophy in Alzheimer disease. AJNR Am J Neuroradiol 2009;30:578–80

    Abstract/FREE Full Text
29. 29.↵
    1. Murray ME,
    2. Graff-Radford NR,
    3. Ross OA,
    4. et al

    . Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011;10:785–96

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Bacskai BJ,
    2. Hickey GA,
    3. Skoch J,
    4. et al

    . Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A 2003;100:12462–67

    Abstract/FREE Full Text
31. 31.↵
    1. Klunk WE,
    2. Wang Y,
    3. Huang GF,
    4. et al

    . The binding of 2-(4′-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003;23:2086–92

    Abstract/FREE Full Text
32. 32.↵
    1. Bacskai BJ,
    2. Frosch MP,
    3. Freeman SH,
    4. et al

    . Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007;64:431–44

    CrossRefPubMed
33. 33.↵
    1. Ikonomovic MD,
    2. Klunk WE,
    3. Abrahamson EE,
    4. et al

    . Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630–45

    Abstract/FREE Full Text
34. 34.↵
    1. Rabinovici GD,
    2. Jagust WJ

    . Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol 2009;21:117–28

    PubMedWeb of Science
35. 35.↵
    1. Johnson KA,
    2. Fox NC,
    3. Sperling RA,
    4. et al

    . Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006213

    Abstract/FREE Full Text
36. 36.↵
    1. Holtzman DM

    . CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiol Aging 2011;32 Suppl 1:S4–9

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Laino C

    . News from the American Neurological Association Annual Meeting: anti-amyloid-beta drug modestly slows cognitive decline in mild to moderate AD. Neurol Today 2012;12:34–38
38. 38.↵
    1. Jack CR Jr.,
    2. Barkhof F,
    3. Bernstein MA,
    4. et al

    . Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement 2011;7:474–85.e4

    CrossRefPubMed
39. 39.↵
    1. Jack CR Jr.

    . Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology 2012;263:344–61

    CrossRefPubMed
40. 40.↵
    1. Dubois B,
    2. Feldman HH,
    3. Jacova C,
    4. et al

    . Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118–27

    CrossRefPubMedWeb of Science
41. 41.↵
    1. McKhann GM,
    2. Knopman DS,
    3. Chertkow H,
    4. et al

    . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263–69

    CrossRefPubMedWeb of Science
42. 42.↵
    1. Albert MS,
    2. DeKosky ST,
    3. Dickson D,
    4. et al

    . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270–79

    CrossRefPubMedWeb of Science
43. 43.↵
    Highlights of prescribing information: Amyvid (florbetapir F18 injection). Silver Spring, MD: Food and Drug Administration (http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202008s000lbl.pdf)
44. 44.↵
    1. Mucke L,
    2. Selkoe DJ

    . Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2012;2:a006338

    Abstract/FREE Full Text
45. 45.↵
    1. Storandt M,
    2. Mintun MA,
    3. Head D,
    4. et al

    . Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 2009;66:1476–81

    CrossRefPubMedWeb of Science
46. 46.↵
    1. Schott JM,
    2. Bartlett JW,
    3. Fox NC,
    4. et al

    . Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ 1–42. Ann Neurol 2010;68:825–34

    CrossRefPubMedWeb of Science
47. 47.↵
    1. Tarawneh R,
    2. D'Angelo G,
    3. Macy E,
    4. et al

    . Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 2011;70:274–85

    CrossRefPubMed
48. 48.↵
    1. McEvoy LK,
    2. Brewer JB

    . Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. Imaging Med 2012;4:343–57

    CrossRefPubMed
49. 49.↵
    1. Bateman RJ,
    2. Xiong C,
    3. Benzinger TL,
    4. et al

    . Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795–804

    CrossRefPubMedWeb of Science
50. 50.↵
    1. Selkoe DJ

    . Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 2011;17:1060–65

    CrossRefPubMed
51. 51.
    1. Bakkour A,
    2. Morris JC,
    3. Dickerson BC

    . The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology 2009;72:1048–55

    CrossRef
52. 52.
    1. Costafreda SG,
    2. Dinov ID,
    3. Tu Z,
    4. et al

    . Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. Neuroimage 2011;56:212–19

    CrossRefPubMedWeb of Science
53. 53.
    1. den Heijer T,
    2. van der Lijn F,
    3. Koudstaal PJ,
    4. et al

    . A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. Brain 2010;133:1163–72

    Abstract/FREE Full Text
54. 54.
    1. Desikan RS,
    2. Cabral HJ,
    3. Fischl B,
    4. et al

    . Temporoparietal MR imaging measures of atrophy in subjects with mild cognitive impairment that predict subsequent diagnosis of Alzheimer disease. AJNR Am J Neuroradiol 2009;30:532–38

    Abstract/FREE Full Text
55. 55.
    1. Heister D,
    2. Brewer JB,
    3. Magda S,
    4. et al

    . Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 2011;77:1619–28

    CrossRefPubMed
56. 56.
    1. Jack CR Jr.,
    2. Wiste HJ,
    3. Vemuri P,
    4. et al

    . Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133:3336–48

    Abstract/FREE Full Text
57. 57.
    1. Kovacevic S,
    2. Rafii MS,
    3. Brewer JB,
    4. et al

    . High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment. Alzheimer Dis Assoc Disord 2009;23:139–45

    CrossRefPubMed
58. 58.
    1. Sluimer JD,
    2. van der Flier WM,
    3. Karas GB,
    4. et al

    . Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. Eur Radiol 2009;19:2826–33

    CrossRefPubMedWeb of Science
59. 59.
    1. Vemuri P,
    2. Wiste HJ,
    3. Weigand SD,
    4. et al

    . MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009;73:294–301

    CrossRef
60. 60.
    1. Westman E,
    2. Cavallin L,
    3. Muehlboeck JS,
    4. et al

    . Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer's disease. PLoS One 2011;6:e22506

    CrossRefPubMed
61. 61.
    1. Dickerson BC,
    2. Stoub TR,
    3. Shah RC,
    4. et al

    . Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 2011;76:1395–402

    CrossRefPubMed
62. 62.
    1. Dickerson BC,
    2. Wolk DA

    . Alzheimer's Disease Neuroimaging Initiative. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology 2012;78:84–90

    CrossRefPubMed
63. 63.
    1. Adams HP Jr.,
    2. del Zoppo G,
    3. Alberts MJ,
    4. et al

    . Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655–711

    Abstract/FREE Full Text